BAVA:VIE
Bavarian Nordic A/S
28,96 €
arrow_downward
-0,55%(-0,16) 1D
2. 10., 17:36:00 GMT+2 · EUR
search
Všechny symboly
| Symbol | Cena | Změna | Změna (%) |
|---|
insights_autoGenerování hlavních statistik pro BAVA…
Otevřít
28,46 €
Max.
28,98 €
Min.
28,46 €
Trž. kap.
2,61 mld.
Prům. obj.
65,00
Objem
0,00
52týd. max.
32,47 €
52týd. min.
22,96 €
Počet zaměstnanců
2 tis.
Otevřít
28,46 €
Max.
28,98 €
Min.
28,46 €
Trž. kap.
2,61 mld.
Prům. obj.
65,00
Objem
0,00
52týd. max.
32,47 €
52týd. min.
22,96 €
Počet zaměstnanců
2 tis.
Zpravodajské články
Z webových zdrojů a od partnerů z oblasti zpravodajství
CNBC
·
před 1 hodinou
Friday's rally in the S&P 500 might not be enough, but Linde is out of this world
Simply Wall Street
·
před 36 minutami
Nebius Group (NBIS) Acquires Inference Specialist To Make Token Factory More Efficient
Yahoo
·
před 1 hodinou
Florida bank celebrates 100th anniversary by ringing NASDAQ bell
The Motley Fool
·
před 5 hodinami
If the Stock Market Crashes, Young Investors in Their 20s Might Want to Buy This Nasdaq ETF and Hold It Until Retirement
Profil
Bavarian Nordic A/S is a Danish biotechnology company focused on the development, manufacturing and commercialization of vaccines. The company is headquartered in Hellerup, Denmark, with manufacturing facilities in Kvistgård, Denmark and Thörishaus near Bern, Switzerland. The company has research and development facilities in Martinsried, Germany, as well as offices in USA, Canada, and France. The company uses viral vectors and virus-like particles in its research and development.
In July 2025, the company agreed to be acquired by private equity firms Permira and Nordic Capital for 19 billion kr. However, in November, the acquisition failed to gain sufficient support from Bavarian Nordic's shareholders, leading to its termination.
In 2026, Bavarian Nordic was ranked second in Time Magazine's World Most Impactful Companies. Wikipedia
Informace o Bavarian Nordic A/S
Generální ředitelPaul Chaplin
Zaměstnanci1,91 tis.
Založeno1. 7. 1992
Ústředí-
Odvětví-